CGTC - New guidance on the development and marketing of ATMPs in the UK and EU in the post-BREXIT landscape

  • Published on 13th December 2021 by Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult has outlined the latest guidance on the development and marketing of ATMPs in the UK.

The UK is now a third country with respect to the EU and as such there have been substantial regulatory changes that must be considered in the development, manufacture, and supply of ATMPs (licensed or for clinical trial).

The guidance covers legislative changes as a result of the United Kingdom leaving the European Union. It includes topics such as clinical trials, ATMP classifications, UK Marketing Authorisations, UK Paediatric Investigation Plans, orphan drug designation, MHRA submission platform and advice meetings.

The current approach for CGTC on the management of the changes in regulatory areas resulting from Brexit is to continue to monitor, review, and ensure compliance with the relevant requirements for the development and manufacture of ATMPs, the conduct of clinical trials and marketing authorisation applications within the UK, the EU, and international regions. 

With regards to Brexit, divergences between EU and UK law are being actively monitored and the impact to regulatory strategy and long-term plans will be communicated to our collaborators.

Please view the new guidance here.

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.